Does EVOLOCUMAB Cause Injection site induration? 229 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 229 reports of Injection site induration have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.2% of all adverse event reports for EVOLOCUMAB.
229
Reports of Injection site induration with EVOLOCUMAB
0.2%
of all EVOLOCUMAB reports
1
Deaths
4
Hospitalizations
How Dangerous Is Injection site induration From EVOLOCUMAB?
Of the 229 reports, 1 (0.4%) resulted in death, 4 (1.7%) required hospitalization.
Is Injection site induration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 229 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Injection site induration?
ETANERCEPT (1,451)
NALTREXONE (866)
ADALIMUMAB (577)
GLATIRAMER (382)
DUPILUMAB (376)
INTERFERON BETA-1A (254)
ENBREL (218)
LEUPROLIDE (207)
IXEKIZUMAB (177)
HYDROXYPROGESTERONE CAPROATE (158)
Which EVOLOCUMAB Alternatives Have Lower Injection site induration Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE